Phase 1/2a study of sintilimab in combination with RC88 in Chinese patients with advanced solid tumors

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Feb 2024 According to RemeGen media release, RemeGen announced its RC88 combined with Sintilimab injection to treat advanced malignant entities in cooperation with Innovent Biologics was approved by the State Food and Drug Administrations for Center for Drug Evaluation (CDE).
30 Jun 2023 New trial record
26 Jun 2023 According to an Innovent Biologics media release, the company entered into a clinical trial collaboration and supply agreement with RemeGen Co., Ltd. Innovent will provide clinical drug supplies of TYVYT (sintilimab injection) during the clinical trial collaboration and RemeGen will conduct the studies.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com